Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by Catalent Gene Therapy Expert
(World News Science)

SOMERSET, N.J. - September 22, 2020 - Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, Catalent Cell & Gene Therapy, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 - October 1, 2020. On Sept. 30 at 4:05 p.m. EST, Dr. Buchman will present...